China National Medicines (600511) Fundamentals 2026 — P/E 10.3x, Revenue Analysis | SniperIQ
China National Medicines (600511) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥20.8B, trading at ¥27.55 on the SHH. This SniperIQ fundamentals page covers China National Medicines's valuation (P/E 10.3x, P/B 1.1x), profitability (net margin 3.8%), revenue (¥52.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China National Medicines's market cap?
China National Medicines (600511) has a market capitalization of approximately ¥20.8B, trading at ¥27.55 on the SHH. Market cap moves with the live share price.
What is China National Medicines's P/E ratio?
China National Medicines's trailing twelve-month P/E ratio is 10.3x, with a price-to-book (P/B) of 1.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China National Medicines?
China National Medicines runs a net profit margin of 3.8%, a gross margin of 6.4%, and an operating margin of 4.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China National Medicines generate?
China National Medicines reported revenue of ¥52.5B for fiscal year 2025, with net income of ¥2.0B and earnings per share (EPS) of 2.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China National Medicines pay a dividend?
China National Medicines offers a trailing dividend yield of about 2.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China National Medicines financially healthy?
China National Medicines carries a debt-to-equity ratio of 0.16x and a current ratio of 2.18x, with a market beta of 0.18. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China National Medicines a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China National Medicines (600511) the key facts are: market cap ¥20.8B, P/E 10.3x, revenue ¥52.5B, 52-week range 25.11-31.18. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China National Medicines's full fundamentals live
Get China National Medicines's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.